The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Mara Sherman, PhD, was awarded the Mark Foundation 2025 Emerging Leader Award, which honored five early-career scientists ...

Tea will be served at 10:15 a.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

We treat every type of cancer, including the most important one: yours. With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need ...

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Tea will be served at 1:45 p.m., immediately preceding the seminar.AudienceThis seminar is open to the research community.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.